These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Melanoma brain metastases and vemurafenib: need for further investigation. Rochet NM; Dronca RS; Kottschade LA; Chavan RN; Gorman B; Gilbertson JR; Markovic SN Mayo Clin Proc; 2012 Oct; 87(10):976-81. PubMed ID: 23036672 [TBL] [Abstract][Full Text] [Related]
24. Phase IB Study of Vemurafenib in Combination with Irinotecan and Cetuximab in Patients with Metastatic Colorectal Cancer with BRAFV600E Mutation. Hong DS; Morris VK; El Osta B; Sorokin AV; Janku F; Fu S; Overman MJ; Piha-Paul S; Subbiah V; Kee B; Tsimberidou AM; Fogelman D; Bellido J; Shureiqi I; Huang H; Atkins J; Tarcic G; Sommer N; Lanman R; Meric-Bernstam F; Kopetz S Cancer Discov; 2016 Dec; 6(12):1352-1365. PubMed ID: 27729313 [TBL] [Abstract][Full Text] [Related]
25. Targeting hyperactivation of the AKT survival pathway to overcome therapy resistance of melanoma brain metastases. Niessner H; Forschner A; Klumpp B; Honegger JB; Witte M; Bornemann A; Dummer R; Adam A; Bauer J; Tabatabai G; Flaherty K; Sinnberg T; Beck D; Leiter U; Mauch C; Roesch A; Weide B; Eigentler T; Schadendorf D; Garbe C; Kulms D; Quintanilla-Martinez L; Meier F Cancer Med; 2013 Feb; 2(1):76-85. PubMed ID: 24133630 [TBL] [Abstract][Full Text] [Related]
26. Identification of multiple mechanisms of resistance to vemurafenib in a patient with BRAFV600E-mutated cutaneous melanoma successfully rechallenged after progression. Romano E; Pradervand S; Paillusson A; Weber J; Harshman K; Muehlethaler K; Speiser D; Peters S; Rimoldi D; Michielin O Clin Cancer Res; 2013 Oct; 19(20):5749-57. PubMed ID: 23948972 [TBL] [Abstract][Full Text] [Related]
27. The discovery of vemurafenib for the treatment of BRAF-mutated metastatic melanoma. Kim A; Cohen MS Expert Opin Drug Discov; 2016 Sep; 11(9):907-16. PubMed ID: 27327499 [TBL] [Abstract][Full Text] [Related]
28. Pilomyxoid astrocytoma treated successfully with vemurafenib. Skrypek M; Foreman N; Guillaume D; Moertel C Pediatr Blood Cancer; 2014 Nov; 61(11):2099-100. PubMed ID: 24821190 [TBL] [Abstract][Full Text] [Related]
29. BRAF-mutated clear cell sarcoma is sensitive to vemurafenib treatment. Protsenko SA; Semionova AI; Komarov YI; Aleksakhina SN; Ivantsov AO; Iyevleva AG; Imyanitov EN Invest New Drugs; 2015 Oct; 33(5):1136-43. PubMed ID: 26286452 [TBL] [Abstract][Full Text] [Related]
30. Long-term vemurafenib treatment drives inhibitor resistance through a spontaneous KRAS G12D mutation in a BRAF V600E papillary thyroid carcinoma model. Danysh BP; Rieger EY; Sinha DK; Evers CV; Cote GJ; Cabanillas ME; Hofmann MC Oncotarget; 2016 May; 7(21):30907-23. PubMed ID: 27127178 [TBL] [Abstract][Full Text] [Related]
31. Overcoming resistance in a Schmid T; Buess M Curr Oncol; 2018 Jun; 25(3):e217-e219. PubMed ID: 29962848 [TBL] [Abstract][Full Text] [Related]
32. Long-Term Survival of a Patient With Non-Small-Cell Lung Cancer Harboring a V600E Mutation in the BRAF Oncogene. Myall NJ; Neal JW; Cho-Phan CD; Zhou LY; Stehr H; Zhou L; Diehn M; Wakelee HA Clin Lung Cancer; 2016 Mar; 17(2):e17-21. PubMed ID: 26776917 [No Abstract] [Full Text] [Related]
33. An open-label, multicentre safety study of vemurafenib in patients with BRAF Larkin J; Brown MP; Arance AM; Hauschild A; Queirolo P; Vecchio MD; Ascierto PA; Krajsová I; Schachter J; Neyns B; Garbe C; Sileni VC; Mandalà M; Gogas H; Espinosa E; Hospers G; Lorigan P; Nyakas M; Guminski A; Liszkay G; Rutkowski P; Miller W; Donica M; Makrutzki M; Blank C Eur J Cancer; 2019 Jan; 107():175-185. PubMed ID: 30580112 [TBL] [Abstract][Full Text] [Related]
34. Dramatic response of vemurafenib-induced cutaneous lesions upon switch to dual BRAF/MEK inhibition in a metastatic melanoma patient. Peters S; Bouchaab H; Zimmerman S; Bucher M; Gaide O; Letovanec I; Homicsko K; Michielin O Melanoma Res; 2014 Oct; 24(5):496-500. PubMed ID: 25185693 [TBL] [Abstract][Full Text] [Related]
35. Investigation of patterns of nodal metastases in BRAF mutant lung cancer. McEvoy SH; Halpenny DF; Viteri-Jusué A; Hayes SA; Plodkowski AJ; Riely GJ; Ginsberg MS Lung Cancer; 2017 Jun; 108():62-65. PubMed ID: 28625649 [TBL] [Abstract][Full Text] [Related]
36. Kulkarni A; Al-Hraishawi H; Simhadri S; Hirshfield KM; Chen S; Pine S; Jeyamohan C; Sokol L; Ali S; Teo ML; White E; Rodriguez-Rodriguez L; Mehnert JM; Ganesan S Clin Cancer Res; 2017 Sep; 23(18):5631-5638. PubMed ID: 28539463 [No Abstract] [Full Text] [Related]
37. V600E BRAF versus Non-V600E BRAF Mutated Lung Adenocarcinomas: Cytomorphology, Histology, Coexistence of Other Driver Mutations and Patient Characteristics. Salimian KJ; Fazeli R; Zheng G; Ettinger D; Maleki Z Acta Cytol; 2018; 62(2):79-84. PubMed ID: 29320776 [TBL] [Abstract][Full Text] [Related]
38. Cutaneous manifestations of vemurafenib therapy for metastatic melanoma. Owen JL; Lopez IE; Desai SR J Drugs Dermatol; 2015 May; 14(5):509-10. PubMed ID: 25942671 [TBL] [Abstract][Full Text] [Related]
39. Granuloma Annulare Secondary to Vemurafenib Therapy for Lung Adenocarcinoma. Jenkinson HA; Siroy AE; Choksi A J Drugs Dermatol; 2017 Oct; 16(10):1050-1052. PubMed ID: 29036262 [TBL] [Abstract][Full Text] [Related]
40. Vemurafenib pharmacokinetics and its correlation with efficacy and safety in outpatients with advanced BRAF-mutated melanoma. Kramkimel N; Thomas-Schoemann A; Sakji L; Golmard J; Noe G; Regnier-Rosencher E; Chapuis N; Maubec E; Vidal M; Avril M; Goldwasser F; Mortier L; Dupin N; Blanchet B Target Oncol; 2016 Feb; 11(1):59-69. PubMed ID: 26208946 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]